Related SPLV New ETFs Look To Separate Themselves Sector Surprises In A Popular Low Vol ETF
Related A Low Vol ETF Love Affair Mid Caps Like The Low Volatility Treatment, Too
With sectors such as technology and consumer discretionary performing well this year, it might surprise some investors to learn that low volatility exchange-traded funds have not been all that bad. Actually, the PowerShares S&P 500 Low Volatility Portfolio (NYSE: SPLV), the fund credited with starting the low volatility ETF craze, is up 10 percent year to date, slightly outpacing the S&P 500.
Hot Performing Stocks To Own Right Now: Real Goods Solar, Inc.(RGSE)
- [By Ashley Moore]
Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:
Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%
- [By Lisa Levin]
Shares of Real Goods Solar, Inc. (NASDAQ: RGSE) got a boost, shooting up 22 percent to $2.98 after dropping 7.89 percent on Monday. RGS Energy disclosed that it has completed its $11.5 million public offering of common stock and warrants.
- [By Peter Graham]
A long term performance chart shows Vivint Solar Holdings and fellow small cap solar installation stock Sunrun Inc (NASDAQ: RUN) below their IPO prices while Real Goods Solar, Inc (NASDAQ: RGSE)has imploded from its previous highs:
- [By Lisa Levin]
Shares of Real Goods Solar, Inc. (NASDAQ: RGSE) got a boost, shooting up 15 percent to $1.26 after the company issued a business update. RGS Energy expects Q1 sales of $1.96 million, up from $670,000 in the fourth quarter.
- [By Peter Graham]
A long term performance chart shows Vivint Solar Holdings along with small cap solar installation stock Sunrun Inc (NASDAQ: RUN) below their IPO prices while Real Goods Solar, Inc (NASDAQ: RGSE)has imploded after being a highflyer:
Hot Performing Stocks To Own Right Now: First Horizon National Corporation(FHN)
- [By Lisa Levin] Related WFC Why Bank ETFs Fell On Friday Despite Decent Earnings Phil's Stock World: Funtime Friday Earnings Season Starts Today Rising Book Values and Margins of Safety (GuruFocus)
Related C Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week Why Bank ETFs Fell On Friday Despite Decent Earnings Palo Capital, Inc. Buys Citigroup Inc, Schlumberger, NetApp Inc, Sells Citrix Systems Inc, … (GuruFocus) Companies Reporting Before The Bell
Wells Fargo & Co (NYSE: WFC) is estimated to report quarterly earnings at $1.02 per share on revenue of $22.51 billion.
Citigroup Inc (NYSE: C) is projected to report quarterly earnings at $1.26 per share on revenue of $17.71 billion.
JPMorgan Chase & Co. (NYSE: JPM) is expected to report quarterly earnings at $1.65 per share on revenue of $25.61 billion.
PNC Financial Services Group Inc (NYSE: PNC) is projected to report quarterly earnings at $2.02 per share on revenue of $4.00 billion.
First Republic Bank (NYSE: FRC) is estimated to report quarterly earnings at $1.1 per share on revenue of $675.70 million.
First Horizon National Corp (NYSE: FHN) is projected to report quarterly earnings at $0.28 per share on revenue of $337.89 million.
Hot Performing Stocks To Own Right Now: Sarepta Therapeutics, Inc.(SRPT)
- [By Dan Caplinger]
Yet some stocks didn’t participate in the rally, instead contending with negative news of their own. Zoe’s Kitchen (NYSE:ZOES), GOL Lineas Aereas Inteligentes (NYSE:GOL), and Sarepta Therapeutics (NASDAQ:SRPT) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.
- [By Chris Lange]
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Tuesday following its presentation at the JPMorgan Healthcare Conference. The companys Duchenne muscular dystrophy (DMD) drug, Exondys 51, generated better than expected sales clocking in at $5.4 million in the fourth quarter. Previously, this DMD treatment was approved by the FDA just as recently as September 2016.
- [By Ben Levisohn]
After surveying 30 neurologists, Baird’s Brian Skorney and Neena Bitritto-Garg contend that the Street might be underestimating sales of Sarepta Therapeutics (SRPT) Exondys 51 treatment for patients with Duchenne muscular dystrophy. They explain why: